CLEO Establishes U.S. Reimbursement Pathway
Open PDF
| Stock | Cleo Diagnostics Ltd (COV.ASX) |
|---|---|
| Release Time | 20 May 2026, 9:25 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
CLEO Establishes U.S. Reimbursement Pathway
Key Points
- CLEO to enter U.S. market under CPT code 81599 post-FDA clearance
- Reimbursement levels estimated at ~US$500-US$900 per test
- Strategy aims for long-term reimbursement and commercial scale
Full Summary
Cleo Diagnostics Ltd (ASX:COV) has outlined its U.S. reimbursement strategy for its Pre-Surgical Ovarian Cancer Test, set to launch immediately post-FDA clearance using the CPT code 81599. This code allows for early revenue generation and data collection, crucial for securing a dedicated CPT code. Reimbursement rates are estimated at $500-$900 per test, based on similar diagnostic tests. The company aims to apply for a dedicated CPT code after establishing clinical use and evidence, which will provide consistent reimbursement and broader adoption.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In